Hematology Consults

Thrombocytopenia

A practical approach to confirming the count, recognizing emergencies, narrowing the differential, calculating HIT and TTP probability, and using restrictive platelet-transfusion thresholds.

Audience: internal medicine residents Last reviewed: July 2026
On this page
Quick approach Emergencies Confirm the count Initial workup Diagnostic patterns 4Ts and PLASMIC HIT TTP ITP Platelet transfusion Questions References

Quick approach

Five questions to answer first

1. Is the count real? Review the smear and repeat the count in an alternative anticoagulant tube when platelet clumping is possible.
2. Is the patient bleeding? Assess hemodynamics, neurologic symptoms, mucosal bleeding, gastrointestinal bleeding, hematuria, and procedure needs.
3. Is it isolated? Anemia, leukopenia, blasts, schistocytes, or abnormal coagulation studies substantially change the differential.
4. Is the decline acute? Compare with the baseline count and review the percentage fall, not only the absolute nadir.
5. Is there thrombosis? Thrombocytopenia with thrombosis should raise concern for HIT, thrombotic microangiopathy, antiphospholipid syndrome, DIC, or malignancy-associated thrombosis.
Do not transfuse by number alone Use the indication, bleeding status, procedure, mechanism, and current transfusion guideline.

Red flags requiring urgent escalation

  • Major, critical-site, or hemodynamically significant bleeding
  • New neurologic deficit, severe headache, seizure, or confusion
  • Thrombocytopenia plus microangiopathic hemolytic anemia or schistocytes
  • Suspected HIT with new thrombosis, skin necrosis, or acute systemic reaction after heparin
  • Blasts, promyelocytes, or concern for acute leukemia
  • Rapidly falling platelets with prolonged PT/aPTT, low fibrinogen, and elevated D-dimer
  • Pregnancy with hemolysis, liver injury, hypertension, or TMA
  • Platelets extremely low with active mucosal bleeding
Do not wait for the classic TTP pentad. Thrombocytopenia plus microangiopathic hemolytic anemia is enough to trigger urgent TTP evaluation when no better explanation is present. Obtain an ADAMTS13 sample before plasma therapy when feasible, but do not delay emergency treatment in a patient with high clinical probability. [4]

1. Confirm that thrombocytopenia is real

  1. Review the peripheral smear for platelet clumps, satellitism, giant platelets, schistocytes, blasts, dysplasia, and other cytopenias.
  2. If EDTA-dependent clumping is suspected, repeat the platelet count using a citrate or other laboratory-approved alternative tube.
  3. Compare with previous counts to determine whether the finding is new, chronic, stable, or rapidly progressive.
  4. Review whether the analyzer reported flags or whether the count may be inaccurate because of giant platelets.
Pseudothrombocytopenia is a laboratory artifact. Do not expose the patient to unnecessary transfusion, steroids, or invasive workup until an unexpectedly low count has been confirmed.

2. Initial history, examination, and laboratory evaluation

History

  • Prior platelet counts and timing of the decline
  • Bleeding symptoms and new thrombosis
  • Heparin exposure within the preceding 100 days
  • New medications, antibiotics, antiepileptics, or chemotherapy
  • Recent infection, vaccination, surgery, or transfusion
  • Alcohol use and nutritional history
  • Liver disease, autoimmune disease, malignancy, or pregnancy
  • Family history of thrombocytopenia or bleeding

Examination

  • Petechiae, purpura, ecchymoses, and mucosal bleeding
  • Neurologic status
  • Fever, hypotension, and evidence of infection
  • Hepatomegaly or splenomegaly
  • Lymphadenopathy
  • Signs of thrombosis or digital ischemia
  • Heparin injection-site necrosis
  • Pregnancy-related hypertension or organ injury

Common initial tests

  • Repeat CBC with differential
  • Peripheral blood smear
  • Reticulocyte count
  • Creatinine, AST, ALT, bilirubin, and albumin
  • LDH, haptoglobin, and indirect bilirubin when hemolysis is possible
  • PT/INR, aPTT, fibrinogen, and D-dimer when DIC is possible
  • Pregnancy testing when relevant
  • HIV and hepatitis C testing when appropriate
  • B12, folate, or copper testing when clinically indicated
  • HIT or ADAMTS13 testing only within the appropriate clinical pathway

3. Pattern recognition

Pattern Important possibilities Helpful clues
Isolated thrombocytopenia ITP, drug-induced immune thrombocytopenia, viral infection, pseudothrombocytopenia, inherited thrombocytopenia Otherwise preserved CBC, no schistocytes, normal coagulation tests, compatible history
Thrombocytopenia plus hemolytic anemia TTP, HUS, complement-mediated TMA, severe hypertension, pregnancy-associated TMA, mechanical hemolysis, DIC Schistocytes, high LDH, low haptoglobin, indirect hyperbilirubinemia, organ injury
Thrombocytopenia plus prolonged PT/aPTT DIC, advanced liver disease, massive transfusion, anticoagulant effect Fibrinogen trend, D-dimer, clinical trigger, factor pattern, liver function
Thrombocytopenia plus thrombosis HIT, TTP/TMA, DIC, antiphospholipid syndrome, malignancy, vaccine-related immune thrombosis in the proper context Exposure timing, 4Ts score, smear, coagulation tests, organ injury, thrombosis location
Pancytopenia Marrow suppression or infiltration, acute leukemia, myelodysplasia, aplasia, severe nutritional deficiency, hypersplenism, infection Smear, reticulocyte response, medication history, imaging, marrow evaluation when indicated
Thrombocytopenia with splenomegaly Portal hypertension, chronic liver disease, lymphoid malignancy, infection, infiltrative disease Liver studies, imaging, additional cytopenias, lymphadenopathy

Medication review

The medication timeline matters more than memorizing a single list. Potential causes include heparin, quinine or quinidine, sulfonamides, vancomycin, beta-lactams, linezolid, valproate, chemotherapy, immune-checkpoint inhibitors, and other agents. Determine whether the drug causes immune destruction, marrow suppression, TMA, or another mechanism.

Interactive tools

Clinical probability calculators

These scores organize clinical probability. They do not replace specialist input, reassessment, laboratory interpretation, or urgent treatment when the syndrome is strongly suspected.

4Ts score for suspected HIT

Complete all four components.

ASH categories: 0–3 low, 4–5 intermediate, 6–8 high probability.

PLASMIC score for severe ADAMTS13 deficiency

Select every criterion that is present.

Typical categories: 0–4 low, 5 intermediate, 6–7 high predicted probability. Use in adults with a suspected thrombotic microangiopathy—not as a general thrombocytopenia score.

4. Heparin-induced thrombocytopenia

HIT is an immune, highly prothrombotic syndrome. The platelet count often falls by more than 50%, while the nadir may remain above 20 × 10⁹/L. The percentage decline and timing are therefore more informative than waiting for profound thrombocytopenia.

Use the 4Ts before ordering laboratory testing

  • Low probability, 0–3: ASH recommends against routine HIT laboratory testing unless important information is missing or the score is uncertain. [1]
  • Intermediate or high probability, 4–8: stop heparin, obtain an immunoassay, and begin an appropriate non-heparin anticoagulant strategy based on bleeding risk and clinical probability. [1]
  • If the immunoassay is positive and a functional assay is available, obtain functional confirmation unless the clinical and immunoassay findings are already strongly convincing. [1]
Do not start warfarin during acute HIT before platelet recovery. Platelet transfusion is not routine in acute HIT but may be considered for active bleeding or very high bleeding risk. [1]

5. Thrombotic thrombocytopenic purpura

TTP is a thrombotic microangiopathy associated with severe ADAMTS13 deficiency. An ADAMTS13 activity below 10% is the hallmark laboratory finding, but the result may not be immediately available. [4]

Initial syndrome recognition

  • Thrombocytopenia
  • Microangiopathic hemolytic anemia
  • Schistocytes, elevated LDH, and low haptoglobin
  • Neurologic, cardiac, gastrointestinal, or renal ischemic injury
  • Coagulation testing that may be relatively preserved compared with DIC

Immediate steps when suspicion is high

  1. Contact hematology and the transfusion/apheresis service urgently.
  2. Draw ADAMTS13 activity and inhibitor samples before plasma exchange or plasma infusion when feasible.
  3. Do not delay emergency TTP-directed treatment solely while waiting for the ADAMTS13 result.
  4. Evaluate for alternative TMAs, DIC, severe hypertension, pregnancy-related disease, infection, medications, and complement- mediated TMA.
The 2025 ISTH focused update mainly changed prophylactic management of congenital TTP. The established acute immune-TTP diagnostic and treatment framework remains based on the 2020 guidance. [5]

6. Immune thrombocytopenia

ITP is a diagnosis of exclusion characterized by immune-mediated platelet destruction and impaired production. A typical adult has isolated thrombocytopenia without schistocytes, major coagulation-test abnormalities, or another clear cause.

Before calling it ITP

  • Confirm the count and review the smear
  • Review medications and alcohol exposure
  • Assess for infection, liver disease, splenomegaly, and malignancy
  • Check for additional cytopenias or hemolysis
  • Test for HIV and hepatitis C when appropriate
  • Consider secondary autoimmune disease based on the history

Observation versus initial treatment in adults

For newly diagnosed adult ITP with no more than minor mucocutaneous bleeding, ASH generally favors:

  • Platelets at least 30 × 10⁹/L: observation rather than corticosteroid treatment.
  • Platelets below 30 × 10⁹/L: corticosteroid treatment rather than observation.

These are not rigid rules. Age, anticoagulants, antiplatelet drugs, comorbidities, bleeding phenotype, procedure needs, access to follow-up, and patient preferences matter. [2]

For initial corticosteroid treatment, the established ASH guideline favors a short course rather than prolonged prednisone exposure. Suggested initial options include prednisone 0.5–2 mg/kg/day or dexamethasone 40 mg/day for 4 days, selected according to the clinical situation and need for rapid response. [2]

Life-threatening ITP bleeding is an emergency and is not managed by applying the outpatient platelet threshold alone. Obtain urgent hematology input and follow the institutional critical-bleeding pathway.

7. Platelet-transfusion thresholds

The 2025 AABB/ICTMG guideline supports restrictive platelet transfusion strategies and emphasizes the clinical setting rather than a universal platelet target. [6]

Situation Guideline threshold Important context
Nonbleeding patient receiving chemotherapy or allogeneic stem cell transplant Transfuse when platelets are below 10 × 10³/µL Strong recommendation for hypoproliferative thrombocytopenia. [6]
Adult consumptive thrombocytopenia without major bleeding Transfuse when platelets are below 10 × 10³/µL Conditional recommendation; treat the underlying cause. [6]
Lumbar puncture Transfuse when platelets are below 20 × 10³/µL This is lower than many older institutional defaults. Follow the current local procedural policy. [6]
Central venous catheter placement at a compressible site Transfuse when platelets are below 10 × 10³/µL Conditional recommendation for adults. [6]
Low-risk interventional-radiology procedure Transfuse when platelets are below 20 × 10³/µL Confirm how the planned procedure is categorized locally. [6]
High-risk interventional-radiology procedure Transfuse when platelets are below 50 × 10³/µL Procedure-specific bleeding risk remains important. [6]
Major non-neuraxial surgery Transfuse when platelets are below 50 × 10³/µL Conditional recommendation; active bleeding and platelet dysfunction may change management. [6]
Nonoperative intracranial hemorrhage with platelets above 100 × 10³/µL Do not routinely transfuse platelets Includes adults receiving antiplatelet therapy. [6]
These thresholds do not replace management of active major bleeding, neurosurgical emergencies, qualitative platelet dysfunction, extracorporeal support, obstetric hemorrhage, or massive-transfusion protocols. Follow the applicable local pathway and consult the transfusion service when the indication is unclear.

Situations where routine prophylactic platelets may be harmful or unhelpful

  • Acute HIT without active bleeding or exceptional bleeding risk
  • Suspected TTP without major bleeding requiring rescue support
  • ITP without clinically important bleeding solely to normalize the count
  • Nonoperative intracranial hemorrhage with platelet count above 100 × 10³/µL solely because the patient takes antiplatelet therapy

8. Resident summary

  1. Confirm the platelet count and inspect the smear.
  2. Determine whether the thrombocytopenia is isolated, acute, and associated with bleeding or thrombosis.
  3. Treat thrombocytopenia plus schistocytes and hemolysis as a possible thrombotic microangiopathy until proven otherwise.
  4. Calculate a 4Ts score before ordering HIT testing.
  5. Use PLASMIC only when an adult thrombotic microangiopathy is suspected.
  6. Do not diagnose ITP before excluding pseudothrombocytopenia, medications, infection, liver disease, and marrow disorders.
  7. Use restrictive platelet-transfusion thresholds and the actual indication rather than transfusing to an arbitrary number.
  8. Escalate immediately for major bleeding, neurologic symptoms, suspected TTP, HIT with thrombosis, DIC, or acute leukemia.

9. Knowledge check

Question 1

A clinically stable patient has a platelet count of 42 × 10⁹/L. The smear shows numerous platelet clumps. What is the best next step?

Question 2

A patient’s 4Ts score is 2 with complete and reliable clinical information. What does ASH recommend?

Question 3

A patient has platelets 18 × 10⁹/L, schistocytes, elevated LDH, undetectable haptoglobin, and new confusion. What is the priority?

Question 4

A nonbleeding adult receiving chemotherapy has platelets 8 × 10³/µL. Which platelet-transfusion approach matches the 2025 AABB guideline?

Question 5

A newly diagnosed adult with likely ITP has platelets 46 × 10⁹/L and only scattered petechiae. Which approach most closely matches established ASH guidance?

References

  1. American Society of Hematology. Diagnosis and Management of Heparin-Induced Thrombocytopenia: Pocket Guide. Official guide
  2. Neunert C, et al. American Society of Hematology 2019 Guidelines for Immune Thrombocytopenia. ASH guideline page Pocket guide
  3. Bendapudi PK, et al. Derivation and External Validation of the PLASMIC Score for Rapid Assessment of Adults With Thrombotic Microangiopathies. Lancet Haematology. 2017. PubMed
  4. Zheng XL, et al. ISTH Guidelines for the Diagnosis of Thrombotic Thrombocytopenic Purpura. Journal of Thrombosis and Haemostasis. 2020. Free full text
  5. Zheng XL, et al. 2025 Focused Update of the 2020 ISTH Guidelines for Diagnosis and Management of TTP. ISTH guideline hub Guideline update
  6. Metcalf RA, et al. Platelet Transfusion: 2025 AABB and ICTMG International Clinical Practice Guidelines. JAMA. 2025;334:606–617. JAMA article AABB summary

Educational disclaimer

This page is intended for clinician education and does not replace institutional protocols, hematology consultation, transfusion-service guidance, product labeling, or individualized clinical judgment. Clinical status, active bleeding, pregnancy, procedures, and local laboratory methods may materially alter management.